Skip to main content
. Author manuscript; available in PMC: 2019 May 1.
Published in final edited form as: Breast Cancer Res Treat. 2018 Jan 19;169(1):47–57. doi: 10.1007/s10549-017-4649-y

Fig. 2.

Fig. 2

Efatutazone affects the expression of differentiation markers in MCFDCIS cells. Fold changes of human CK6a & b, CK17, CK8, MUC1, PgR, and ESR1 mRNAs in MCFDCIS cells treated 72 h with 0.01 µM efatutazone analyzed by qRT-PCR and compared to cells treated with vehicle. Mean ± SEM (Student’s t test; n = 3; *p < 0.05 vs vehicle; **p < 0.01 vs vehicle)